KLP Kapitalforvaltning AS Makes New Investment in Arcellx, Inc. (NASDAQ:ACLX)

KLP Kapitalforvaltning AS acquired a new stake in shares of Arcellx, Inc. ( NASDAQ:ACLX – Free Report ) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 6,600 shares of the company’s stock, valued at approximately $506,000.

Other institutional investors and hedge funds have also modified their holdings of the company. RA Capital Management L.P.



raised its holdings in Arcellx by 15.4% during the 3rd quarter. RA Capital Management L.

P. now owns 1,851,479 shares of the company’s stock worth $154,617,000 after buying an additional 247,465 shares during the period. Raymond James Financial Inc.

acquired a new stake in shares of Arcellx during the fourth quarter worth $10,016,000. Geode Capital Management LLC lifted its position in Arcellx by 4.3% in the 3rd quarter.

Geode Capital Management LLC now owns 974,967 shares of the company’s stock valued at $81,434,000 after acquiring an additional 39,781 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Arcellx by 67.

2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 79,936 shares of the company’s stock worth $6,675,000 after purchasing an additional 32,119 shares during the period.

Finally, American Century Companies Inc. bought a new position in Arcellx during the 4th quarter worth about $2,258,000. 96.

03% of the stock is currently owned by institutional investors and hedge funds. Insider Transactions at Arcellx In other news, insider Rami Elghandour sold 38,300 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $62.

02, for a total value of $2,375,366.00. Following the transaction, the insider now directly owns 149,186 shares of the company’s stock, valued at $9,252,515.

72. This represents a 20.43 % decrease in their ownership of the stock.

The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link . Also, insider Christopher Heery sold 3,061 shares of Arcellx stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $77.

17, for a total transaction of $236,217.37. Following the sale, the insider now directly owns 32,456 shares of the company’s stock, valued at $2,504,629.

52. The trade was a 8.62 % decrease in their position.

The disclosure for this sale can be found here . In the last three months, insiders sold 61,069 shares of company stock worth $3,919,051. 6.

24% of the stock is owned by company insiders. Arcellx Price Performance Arcellx ( NASDAQ:ACLX – Get Free Report ) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.

87) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.24).

The business had revenue of $15.27 million for the quarter, compared to the consensus estimate of $27.42 million.

Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%.

Analysts expect that Arcellx, Inc. will post -1.58 earnings per share for the current year.

Analyst Ratings Changes A number of analysts have recently commented on the company. Needham & Company LLC restated a “buy” rating and issued a $105.00 price target on shares of Arcellx in a report on Monday, December 9th.

HC Wainwright restated a “buy” rating and issued a $115.00 target price on shares of Arcellx in a research note on Tuesday, December 10th. Finally, UBS Group raised their price target on shares of Arcellx from $106.

00 to $114.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Thirteen research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company.

According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $108.46.

Get Our Latest Research Report on ACLX Arcellx Company Profile ( Free Report ) Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). Further Reading Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.

com's FREE daily email newsletter ..